HK1073441A1 - 部分脂肪酸氧化抑制劑如雷諾嗪用於治療糖尿病 - Google Patents
部分脂肪酸氧化抑制劑如雷諾嗪用於治療糖尿病Info
- Publication number
- HK1073441A1 HK1073441A1 HK05107050.7A HK05107050A HK1073441A1 HK 1073441 A1 HK1073441 A1 HK 1073441A1 HK 05107050 A HK05107050 A HK 05107050A HK 1073441 A1 HK1073441 A1 HK 1073441A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ranolazine
- diabetes
- administration
- treatment
- fatty acid
- Prior art date
Links
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title 1
- 229940081730 Partial fatty acid oxidation inhibitor Drugs 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229960000213 ranolazine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38278102P | 2002-05-21 | 2002-05-21 | |
US45933203P | 2003-03-31 | 2003-03-31 | |
PCT/US2003/016277 WO2003099281A2 (en) | 2002-05-21 | 2003-05-21 | Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1073441A1 true HK1073441A1 (zh) | 2005-10-07 |
Family
ID=29586970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05107050.7A HK1073441A1 (zh) | 2002-05-21 | 2005-08-16 | 部分脂肪酸氧化抑制劑如雷諾嗪用於治療糖尿病 |
Country Status (17)
Country | Link |
---|---|
US (4) | US20040063717A1 (zh) |
EP (2) | EP2332540A1 (zh) |
JP (1) | JP4546824B2 (zh) |
KR (1) | KR101030943B1 (zh) |
CN (1) | CN100551370C (zh) |
AU (1) | AU2003248558B8 (zh) |
BR (1) | BR0311161A (zh) |
CA (1) | CA2486712C (zh) |
ES (1) | ES2523873T3 (zh) |
HK (1) | HK1073441A1 (zh) |
IL (4) | IL165304A0 (zh) |
MX (1) | MXPA04011530A (zh) |
NO (1) | NO330336B1 (zh) |
NZ (1) | NZ536678A (zh) |
RU (1) | RU2320343C2 (zh) |
WO (1) | WO2003099281A2 (zh) |
ZA (1) | ZA200409331B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063717A1 (en) | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
BRPI0606403A2 (pt) * | 2005-01-06 | 2009-06-23 | Cv Therapeutics Inc | formulações farmacêuticas com liberação sustentada e seus usos |
WO2008101012A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
EP2117549A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
JP2010518181A (ja) | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
AU2008240202A1 (en) * | 2007-04-12 | 2008-10-23 | Cv Therapeutics, Inc. | Ranolazine for enhancing insulin secretion |
KR20100033490A (ko) * | 2007-05-31 | 2010-03-30 | 질레드 팔로 알토 인코포레이티드 | 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진 |
AU2007354300A1 (en) * | 2007-05-31 | 2008-12-04 | Gilead Sciences, Inc. | Method of treating diabetes |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
EA201070914A1 (ru) * | 2008-02-06 | 2011-04-29 | Гайлид Сайэнсиз, Инк. | Применение ранолазина для лечения боли |
US20110250273A1 (en) * | 2008-12-11 | 2011-10-13 | Melford Scientific, LLC | Compositions of proton pump inhibitors, kits and methods of their use to treat diabetes |
JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ, インコーポレイテッド | Cns障害の治療のためのラノラジン |
JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
CN110812344A (zh) * | 2019-12-17 | 2020-02-21 | 卓和药业集团有限公司 | 一种治疗糖尿病合并心绞痛的药物组合物及制备方法 |
GR1010510B (el) * | 2022-06-07 | 2023-07-20 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
GB2202222B (en) * | 1987-03-16 | 1991-03-27 | American Home Prod | Fluorooxirane carboxylates |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
EP0714660B1 (en) | 1989-06-23 | 2002-09-04 | Syntex (U.S.A.) LLC | Ranolazine and related piperazines for protecting skeletal muscles |
US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
JP2002522082A (ja) * | 1998-08-11 | 2002-07-23 | ザ・ガバナーズ・オブ・ザ・ユニバーシティ・オブ・アルバータ | 哺乳類マロニルCoAデカルボキシラーゼの阻害剤、作用物質および拮抗物質を同定するための組成物および方法 |
US6479496B1 (en) | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
US20050245502A1 (en) | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
MXPA02007639A (es) * | 2000-02-18 | 2004-08-23 | Cv Therapeutics Inc | Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva. |
FR2805463B1 (fr) * | 2000-02-25 | 2003-01-24 | Adir | UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE |
US20030220312A1 (en) | 2000-05-11 | 2003-11-27 | G.D. Searle & Co. | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders |
DE60134403D1 (de) | 2000-05-19 | 2008-07-24 | Amylin Pharmaceuticals Inc | Behandlung des akuten koronaren syndroms mit glp-1 |
WO2002007716A2 (en) * | 2000-07-21 | 2002-01-31 | Cv Therapeutics, Inc. | Method for treating angina |
AU2001278045B2 (en) | 2000-07-27 | 2006-08-03 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
KR20080077033A (ko) | 2001-01-26 | 2008-08-20 | 쉐링 코포레이션 | 혈관 질환을 치료하기 위한 스테롤 흡수 억제제와 심혈관제제의 조합물 |
DE60203623T2 (de) * | 2001-07-19 | 2006-01-19 | CV Therapeutics, Inc., Palo Alto | Substituierte piperazinderivate und ihre verwendung als fettsaüre-oxidationsinhibitoren |
US20030220310A1 (en) | 2001-07-27 | 2003-11-27 | Schuh Joseph R. | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
US20050250676A1 (en) | 2001-11-19 | 2005-11-10 | Aventis Pharma Deutschland Gmbh | Method of activating insulin receptor substrate-2 to stimulate insulin production |
EP1472214A2 (en) | 2002-02-08 | 2004-11-03 | SmithKline Beecham Corporation | Compounds for inhibiting insulin secretion and methods related thereto |
US20080109040A1 (en) | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
US20030220344A1 (en) | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
US20040063717A1 (en) | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
US7087394B2 (en) | 2003-03-05 | 2006-08-08 | Metabolex, Inc. | Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-TRP |
US8071645B2 (en) | 2003-06-12 | 2011-12-06 | The Regents Of The University Of Colorado | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
US7060723B2 (en) | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
WO2005070126A2 (en) | 2004-01-08 | 2005-08-04 | The Regents Of The University Of Colorado | Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors |
EP1755579A4 (en) | 2004-05-24 | 2009-06-10 | Univ New York | METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID |
AU2005304421A1 (en) | 2004-11-09 | 2006-05-18 | Gilead Palo Alto, Inc. | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
BRPI0606403A2 (pt) | 2005-01-06 | 2009-06-23 | Cv Therapeutics Inc | formulações farmacêuticas com liberação sustentada e seus usos |
EP1865945A4 (en) | 2005-03-11 | 2008-05-21 | Hong Kong Nitric Oxide Ltd | TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES |
CA2670651A1 (en) | 2006-12-21 | 2008-07-03 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
US20090111826A1 (en) | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
JP2010518181A (ja) | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
US20090312340A1 (en) | 2007-02-13 | 2009-12-17 | Whedy Wang | Use of ranolazine for the treatment of cardiovascular diseases |
WO2008101012A1 (en) | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
EP2117549A1 (en) | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
US20080233191A1 (en) | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
KR20100033490A (ko) | 2007-05-31 | 2010-03-30 | 질레드 팔로 알토 인코포레이티드 | 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진 |
AU2007354300A1 (en) | 2007-05-31 | 2008-12-04 | Gilead Sciences, Inc. | Method of treating diabetes |
EA201070914A1 (ru) | 2008-02-06 | 2011-04-29 | Гайлид Сайэнсиз, Инк. | Применение ранолазина для лечения боли |
EP2337559A2 (en) | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
US20100130436A1 (en) | 2008-11-25 | 2010-05-27 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
JP2012526848A (ja) | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ, インコーポレイテッド | Cns障害の治療のためのラノラジン |
TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
-
2003
- 2003-05-21 US US10/443,314 patent/US20040063717A1/en not_active Abandoned
- 2003-05-21 AU AU2003248558A patent/AU2003248558B8/en not_active Ceased
- 2003-05-21 JP JP2004506805A patent/JP4546824B2/ja not_active Expired - Fee Related
- 2003-05-21 CN CNB038113236A patent/CN100551370C/zh not_active Expired - Fee Related
- 2003-05-21 EP EP10011229A patent/EP2332540A1/en not_active Withdrawn
- 2003-05-21 BR BR0311161-0A patent/BR0311161A/pt not_active Application Discontinuation
- 2003-05-21 MX MXPA04011530A patent/MXPA04011530A/es active IP Right Grant
- 2003-05-21 EP EP03755446.6A patent/EP1505977B1/en not_active Expired - Lifetime
- 2003-05-21 CA CA2486712A patent/CA2486712C/en not_active Expired - Fee Related
- 2003-05-21 KR KR1020047018803A patent/KR101030943B1/ko active IP Right Grant
- 2003-05-21 RU RU2004133670/14A patent/RU2320343C2/ru not_active IP Right Cessation
- 2003-05-21 NZ NZ536678A patent/NZ536678A/en not_active IP Right Cessation
- 2003-05-21 WO PCT/US2003/016277 patent/WO2003099281A2/en active Application Filing
- 2003-05-21 IL IL16530403A patent/IL165304A0/xx unknown
- 2003-05-21 ES ES03755446.6T patent/ES2523873T3/es not_active Expired - Lifetime
-
2004
- 2004-11-18 IL IL165304A patent/IL165304A/en active IP Right Grant
- 2004-11-19 ZA ZA2004/09331A patent/ZA200409331B/en unknown
- 2004-12-20 NO NO20045554A patent/NO330336B1/no not_active IP Right Cessation
-
2005
- 2005-08-16 HK HK05107050.7A patent/HK1073441A1/zh not_active IP Right Cessation
-
2010
- 2010-04-07 US US12/755,931 patent/US8314104B2/en not_active Expired - Fee Related
-
2011
- 2011-06-28 IL IL213806A patent/IL213806A0/en unknown
- 2011-06-28 IL IL213809A patent/IL213809A0/en unknown
-
2012
- 2012-10-18 US US13/655,252 patent/US8883750B2/en not_active Expired - Fee Related
-
2014
- 2014-09-03 US US14/476,650 patent/US20140378465A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1073441A1 (zh) | 部分脂肪酸氧化抑制劑如雷諾嗪用於治療糖尿病 | |
IL151014A0 (en) | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | |
HK1085615A1 (en) | Fatty acid desaturases from fungi | |
SG107672A1 (en) | A method for the esterification of a fatty acid | |
HUP0402629A3 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
EP1592689A4 (en) | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES | |
EP1589969A4 (en) | 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
HK1087103A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
HK1073313A1 (en) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
EP2049442A4 (en) | OXIDATION OF ORGANIC COMPOUNDS | |
FR2850372B1 (fr) | Nouveau reacteur d'oxydation partielle | |
HK1083727A1 (en) | Nutritional formula comprising L (+) lactic acid | |
SG120111A1 (en) | Method for production of acrylic acid | |
AU2003296701A8 (en) | Nematode fatty acid desaturase-like sequences | |
ZA200409433B (en) | Process for the preparation of carboxylic acid esters. | |
AU2003288606A1 (en) | Use of a fatty acid composition for treatment of male infertility | |
EP1660490A4 (en) | CHROMANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | |
GB0230240D0 (en) | Removal of an acid | |
AU2003239025A1 (en) | Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd | |
PL375074A1 (en) | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | |
ZA200409552B (en) | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics. | |
PT1517679E (pt) | Derivados do ácido benzóico substituído na posição orto para o tratamento de resistência à insulina | |
HK1087098A1 (en) | Synthesis of 2-chloromethyl-6-methylbenzoic acid esters | |
AU2003231527A8 (en) | Novel derivatives of carnosic acid | |
AU2003224361A1 (en) | Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20200524 |